Bravtovi™+ Mektovi Improves Survival in BRAF Positive Advanced Colorectal Cancer

-edited

The BEACON clinical trial defines new treatment for BRAF V600E - mutant advanced colorectal cancer

by Dr. C.H. Weaver M.D. Medical Editor updated 4/2019

The NCCN added a new precision cancer medicine treatment regimen to their treatment guidelines for BRAFV600E + metastatic colon cancer. The new treatment combines 3 drugs; the BRAF and MEK inhibitors Bravtovi™(encorafenib), and Mektovi® (binimetinib) and cetuximab for the treatment of patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC). (1) Study results were updated at ESMO and in the J Clin Oncol. March, 2019. (2,3)

About Colorectal Cancer

In the U.S. an estimated 140,250 patients will be diagnosed with cancer of the colon or rectum in 2018, and approximately 50,000 are estimated to die of their disease. BRAF mutations are estimated to occur in 10% to 15% of patients with colorectal cancer and represent a poor prognosis for these patients. The risk of mortality in CRC patients with the BRAF V600E mutation is more than two times higher than for those with wild-type BRAF.(4,5,6)

About Bravtovi™ + MEKTOVI

Bravtovi™ is an oral small molecule BRAF kinase inhibitor and Mektovi® (binimetinib) is an oral small molecule MEK inhibitor which target key enzymes in the MAPK signaling pathway. Inappropriate activation of proteins in this pathway has been shown to occur in many cancers including melanoma, colorectal cancer, non-small cell lung cancer, thyroid and others. In the U.S., Bravtovi™ + Mektovi® are approved for the treatment of unresectable or metastatic melanoma with a BRAF V600E or BRAF V600K mutation, as detected by an FDA-approved test.(7,8)

About BEACON CRC Clinical Trial

The BEACON clinical trial evaluated treatment with Bravtovi™+ Mektovi® and cetuximab in patients with BRAFV600E-mutant mCRC whose disease has progressed after one or two prior regimens. The BEACON trial directly compared Bravtovi™ in combination with cetuximab with or without Mektovi to cetuximab and irinotecan-based therapy. The trial was being conducted at over 200 investigational sites in North America, South America, Europe and the Asia Pacific region.

Data leading to the FDA approval was presented at the ESMO 20th World Congress on Gastrointestinal Cancer. The results of the ongoing BEACON clinical trial demonstrated that:

  • The 3 drug combination of Bravtovi, Mektovi. and cetuximab was generally well-tolerated with no unexpected side effects.
  • Overall response rate was 48%among the 17 patients who received only one prior line of therapy.
  • Average time to cancer progression for patients treated with the triplet was 8 months.
  • Average overall survival is 15.3 months with a median follow-up duration of 18.2 months (range, 16.6-19.8 months).
  • One-year overall survival rate was 62%.

Several precision cancer medicines are now available for the treatment of advanced colon cancer. Bravtovi™ + Mektovi® represent advances in precision therapies targeting the hard to treat BRAFV600E-mutation and will expand the treatment options for this poor prognosis group of patients.

An ongoing study (ANCHOR-CRC) is investigating the effects of triplet therapy as first line treatment for patients with metastatic BRAF V600E-mutant colorectal cancer.

References

  1. <a href="https://www.healio.com/hematology-oncology/gastrointestinal-cancer/news/online/%7B24fa9622-29cb-4137-98a2-629256348577%7D/fda-grants-braftovi-mektovi-plus-erbitux-breakthrough-therapy-designation-for-colorectal-cancer.">https://www.healio.com/hematology-oncology/gastrointestinal-cancer/news/online/%7B24fa9622-29cb-4137-98a2-629256348577%7D/fda-grants-braftovi-mektovi-plus-erbitux-breakthrough-therapy-designation-for-colorectal-cancer.</a>
  2. J Clin Oncol\*.\* 2019 March 20. Epub ahead of print).
  3. LBA-006 ‘BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer’ presented by Scott Kopetz during Session XX: Colorectal Cancer (Part I) on Saturday, 6 July 09:20-10:05 CEST. Annals of Oncology 30 (Supplement 4): iv137–iv151, 2019
  4. De Roock et al., Lancet Oncol, 2010
  5. Global Cancer Facts & Figures 3rd Edition. American Cancer Society. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-3rd-edition.pdf. Accessed January 2018.
  6. Cancer Facts & Figures 2018. American Cancer Society. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf. Accessed January 2018.
  7. Safaee Ardekani G, Jafarnejad SM, Tan L, et al. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One. 2012;7(10):e47054.
  8. http://news.cancerconnect.com/new-braf-mek-combination-promising-for-treatment-of-melanoma/
Comments